Associations - PD-L1 overexpression

PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval Front Mol Biosci - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	tislelizumab Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + MTIG7192A Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + gemcitabine Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	GC Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + pemetrexed Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	avelumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	atezolizumab Sensitive: C1 - Off-label
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	PF-06801591 Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Sarcoma Sarcoma	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	INCMGA0012 Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	camrelizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	GB226 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Prostate Cancer Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	trastuzumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	avelumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	avelumab + IMP 321 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	IMP 321 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PF-06801591 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + LY3500518 Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Head and Neck Cancer Head and Neck Cancer	nivolumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	M7824 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	ipilimumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	nivolumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	olaparib Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	nivolumab + MGCD516 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	ipilimumab + cemiplimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + afatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 + AB928 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymic Carcinoma Thymic Carcinoma	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymic Carcinoma Thymic Carcinoma	pembrolizumab Resistant: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymoma Thymoma	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Sarcoma Sarcoma	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Renal Cell Carcinoma RCC	nivolumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	nivolumab + nimotuzumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	anlotinib + sintilimab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Vulvar Cancer Vulvar Cancer	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: D – Preclinical
PD-L1 overexpression PD-L1 overexpression	Acute Myelogenous Leukemia AML	MGD006 Resistant: D – Preclinical